IRVINE, Calif., March 28, 2006 (PRIMEZONE) -- "As biotechnology companies endeavor to create enhanced drugs and drug delivery systems, we're seeing the technological juggernaut of nanotechnology driving research efforts," stated SmallCap Sentinel analyst D.R. Clark. "The possibilities for nanotechnology are boundless and the effects of nanotech on our everyday lives have now crept ever forward from the Futurist's dreams to the U.S. Patent office."
"Last week, MIV Therapeutics (OTCBB:MIVT) (FWB:MIV), a leading developer of next-generation biocompatible coatings and advanced drug delivery systems for cardiovascular stents and other implantable medical devices, announced the filing of a patent application for its new non-polymeric drug delivery platform technology," said Clark. "The company is calling this a breakthrough in a platform of nanotechnology-based drug delivery structures and coatings which would provide safer and superior storage for the delivery of one or more drugs for the treatment of cardiovascular and other chronic diseases."
The informational report "The Silver Tsunami: Baby Boomers & Biotech Breakthroughs" is available at www.SmallCapSentinel.com and will address stents and stent-related companies including MIV Therapeutics, Inc. (OTCBB:MIVT), Angiotech Pharmaceuticals Inc. (Nasdaq:ANPI), Conor Medsystems Inc. (Nasdaq:CONR) and Guidant Corp. (NYSE:GDT). The report will place specific emphasis on drug eluting stents, their design, application and imperative need.
MIV Therapeutics, Inc. is a developer of next-generation biocompatible stent coatings and drug delivery technologies for cardiovascular stents and for a broad range of implantable medical devices.
Interested parties may view additional information about MIVT via this direct link: http://www.trilogy-capital.com/tcp/mivt/factsheet.html
Individuals may also register to receive free future reports at: http://stockupticks.com/register.html
Statements made herein contain forward-looking statements and are subject to significant risks and uncertainties that affect results. SmallCap Sentinel and StockUpTicks.com are properties of Market Pathways Financial Relations Inc. (MP). MP provides no assurance as to the subject company's plans or ability to effect any proposed actions and cannot project capabilities, intent, resources, or experience.
All information contained herein is based upon sources believed to be reliable but no representation is made as to its accuracy or completeness. This report is neither a solicitation to buy nor an offer to sell securities but is rather a paid advertisement provided for information purposes only and should not be used as the basis for any investment decision. MP is not an investment advisor and this report is not investment advice. MP has been paid fifteen hundred dollars by MIV Therapeutics Corp. for preparation and distribution of this report and other advertising services. This constitutes a conflict of interest as to MP's ability to remain objective in its communication regarding the subject companies.